Send us Fan Mail

While the DESTINY-Breast04 trial, which earned a standing ovation as a practice-changing study for treatment of HER2-low MBC garnered most of the headlines from the ASCO (America Society of Clinical Oncologists) annual meeting in June, it was not the only reason for optimism.  In this episode, the first of a two-part series, Our MBC Life’s Victoria Goldberg and Lynda Weatherby continue to explore what the research shared at ASCO means for us, the patients living with MBC.  

You’ll hear from preeminent oncologists Stephanie Graff, Director of Breast Oncology at the Lifespan Cancer Institute at Brown University  and Hope Rugo (Professor, Department of Medicine (Hematology/Oncology) and Director, Breast Oncology and Clinical Trials Education, UCSF) in this deep dive into two critical studies: DESTINY-Breast04 and TROPICS-02. The latter examined a potential new line of treatment for heavily pre-treated HR-positive, HER2-negative MBC patients.  

ENHERTU (trastuzumab deruxtecan) and TRODELVY (sacituzumab govitecan), the two drugs at the heart of these two trials, are both representatives of a relatively new class of drugs: Antibody Drug Conjugates—ADCs. ADCs are a class of drugs that links a potent chemotherapy drug with an antibody. Unlike traditional chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells. They are a kind of “smart bomb” for cancer treatment—and an extraordinarily promising development for patients.

Our wide-ranging conversations with Dr. Graff and Dr. Rugo cover not only the results of these two trials, but their implications for treatment and the future of breast cancer research.

More info about the show and past episodes is available on our website: www.ourmbclife.org

Got something to share? Feedback?

Email: [email protected]

Follow us on Facebook, Instagram, and twitter @ourmbclife